

VERISOL Clinical Studies
This graph demonstrates the efficiency of VERISOL® Bioactive Collagen Peptides®.
"Skin wrinkles were objectively measured in all subjects, before stating the treatment, after 4 and 8 weeks as well as 4 weeks after the last intake (4-week regression phase)."
-
Two studies have been performed to establish the efficiency (2011 & 2012).
-
Participants included 180 women between the ages of 35 and 60 with normal skin.
-
Each participant recieved either VERISOL or a placebo.
-
Test periods lasted 8 weeks with measurements after 4 & 8 weeks, followed by a 4-week wash out.
-
Aging parameters include skin elasticity and wrinkle volume.
Clinical Study Measurements:
-
Eye wrinkle volume decreased by 20% on average (with the HIGHEST wrinkle reduction at 49%)
-
Procollagen Type I content increased by 65%
-
Elastin content increased by 18%
-
Eye wrinkle volume maintained a decreased amount of 18% 4 weeks after the last in-take.
* 8 weeks clinical study of daily oral VERISOL® Treatment (2500mg) in comparison to placebo administration. Skin Pharmacology and Physiology Vol. 27, No. 1,1014 Issue Release Date: August 2013. Department of Dermatology, University of Kiel, and CRI, Collagen Research Institute, Kiel and Skin Ingestion and Technology, Hamburg, Germany.
VERISOL® Bioactive Collagen Peptides® are registered trademarks of GELITA AG, Germany.

-
Helps to increase joint mobility
-
Promotes optimal physical performance
-
Supports cartilage tissue regeneration

+Joints

FORTIGEL Clinical Studies
FORTIGEL regenerates cartilage tissue in humans *24 week study design of FORTIGEL treatment in comparison of Placebo administration of proteoglycan content in knee cartilage. Harvard/Tufts Study, USA (McAindon,2009).